🚺 Breakthroughs in Women’s Health: Menopause, HIV, Policy Debates and more
This week’s Women’s Health Update covers critical developments, from an FDA advisory committee vote on PTSD treatment and expanded access to HIV therapies, to a new menopause treatment approval and important global policy changes affecting women’s health.
🔬 Key highlights:
🗳️ An FDA advisory committee voted against the efficacy of Rexulti combined with sertraline for PTSD treatment based on available data.
🌐 ViiV Healthcare has expanded its licensing agreement for long-acting injectable cabotegravir to increase access to HIV treatment in 133 countries.
🌡️ Bayer received the first worldwide approval in the UK for Lynkuet (elinzanetant), a hormone-free treatment for moderate to severe menopausal hot flashes.
💊 Merck is initiating global Phase 3 trials for MK-8527, an investigational once-monthly oral pill for HIV pre-exposure prophylaxis (PrEP), including a specific trial in women in sub-Saharan Africa.
🚨 The Trump administration has decided to destroy 9.7 million dollars worth of contraceptives intended for overseas aid, a controversial move costing US taxpayers 167,000 dollars.
📢 Stay Ahead in Women’s Health Research!
✅ Like, share, and subscribe for weekly updates on women’s health, reproductive medicine, neurology, and global public health
#WomensHealth #ReproductiveHealth #PTSD #HIVPrevention #Menopause #Contraceptives #HealthPolicy #Biotech #Pharmaceuticals #LucidQuest #MedicalNews #HealthcareInnovation #ClinicalTrials